Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Frequent occurrence of NECTIN4 amplifications in other cancer types is promising for development of NECTIN4-targeted antibody drug conjugates in a tumour-agnostic context
Findings from the phase I TROPION-PanTumor01 study
New indication concerns combination therapy with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations
Genomic and tumour microenvironment parameters associated with response to PD1 blockade in dMMR cancers
Evidence for efficacy is based on the results from the FIREFLY-1 study
Findings from subgroup analyses of the DESTINY-Breast03 study
It is intended for the treatment of patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations
AI model TORCH achieved robust performance
Evidence for efficacy is based on the results from the QUILT-3.032 study
Evidence for efficacy is based on the results from the ALINA study
Findings from the KEYNOTE-564 study
Findings from the Young Women’s Breast Cancer Study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
